The life history of a botulinum toxin molecule

Toxicon

Volumn 68, Issue , 2013, Pages 40-59

  Simpson, Lance ^a  

^a Inventox Inc   (United States)

Author keywords

Absorption; Antibodies; Botulinum toxin; Distribution; Elimination; Metabolism

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; TETANUS TOXIN;

APOPTOSIS; BIOACCUMULATION; BIODEGRADATION; BOTULISM; CARBOXY TERMINAL SEQUENCE; CHOLINERGIC NERVE; EPITHELIUM CELL; EXTRACELLULAR SPACE; HUMAN; IMMUNIZATION; LD 50; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TOXICOKINETICS; TOXIN STRUCTURE; TRANSCYTOSIS;

ABSORPTION; ADMINISTRATION, INHALATION; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BOTULINUM ANTITOXIN; BOTULINUM TOXINS; BOTULISM; EPITHELIAL CELLS; HUMANS; LETHAL DOSE 50; LIVER; NEURONS; NEUROTOXINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84877619817     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2013.02.014     Document Type: Review

References (105)

1. Adler M., Keller J.E., Sheridan R.E., Deshpande S.S. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 2001, 39:233-243.
2. Ahsan C.R., Hajnoczky G., Maksymowych A.B., Simpson L.L. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 2005, 315:1028-1035.
3. Al-Saleem F.H., Ancharski D.M., Ravichandran E., Joshi S.G., Singh A.K., Gong Y., Simpson L.L. The role of systemic handling in the pathophysiologic action of botulinum toxin. J. Pharmacol. Exp. Ther. 2008, 326:856-863.
4. Al-Saleem F.H., Nasser Z., Olson R.M., Cao L., Simpson L.L. Identification of the factors that govern the ability of therapeutic antibodies to provide post-challenge protection against botulinum toxin: a model for assessing post-challenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J. Pharmacol. Exp. Ther. 2011, 338:503-517.
5. Al-Saleem F.H., Ancharski D.M., Joshi S.G., Elias Md., Singh A., Nasser Z., Simpson L.L. An analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route. Infect. Immun. 2012, 80:4133-4142.
6. Amersdorfer P., Wong C., Chen S., Smith T., Deshpande S., Sheridan R., Finnern R., Marks J.D. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect. Immun. 1997, 65:3743-3752.
7. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M. Botulinum toxin as a biological weapon: medical and public health management. J. Am. Med. Assoc. 2001, 285:1059-1070.
8. Arnon S.S., Schechter R., Maslanka S.E., Jewell N.P., Hatheway C.L. Human botulism immune globulin for the treatment of infant botulism. N. Eng. J. Med. 2006, 354:462-471.
9. Arnon S.S. Creation and development of the public service orphan drug human botulism immune globulin. Pediatrics 2007, 119:785-789.
10. Beers W.H., Reich E. Isolation and characterization of Clostridium botulinum type B toxin. J. Biol. Chem. 1969, 244:4473-4479.
11. Binz T., Kurazono H., Wille M., Frevert J., Wernars K., Niemann H. The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. J. Biol. Chem. 1990, 265:9153-9158.
12. 125I-labeled botulinum neurotoxins with nerve terminals. J. Cell. Biol. 1986, 103:521-534.
13. Blasi J., Chapman E.R., Link E., Binz T., Yamasaki S., de Camilli P., Sudhof T.C., Niemann H., Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993, 365:160-163.
14. Bonventre P.F. Absorption of botulinum toxin from the gastrointestinal tract. Rev. Infect. Dis. 1979, 1:663-667.
15. Scientific and Therapeutic Aspects of Botulinum Toxin 2002, Lippincott William & Wilkins. M.F. Brin, M. Hallett, J. Jankovic (Eds.).
16. Brunger A.T., Jin R., Breidenbach M.A. Highly specific interactions between botulinum neurotoxins and synaptic vesicle proteins. Cell. Mol. Life Sci. 2008, 65:2296-2306.
17. Bullens R.W.M., O'Hanlon G.M., Wagner E., Molenaar P.C., Furukawa K. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J. Neurosci. 2002, 22:6876-6884.
18. Carruthers A., Carruthers J. Botulinum Toxin 2005, Elsevier.
19. Caya J.C., Agni R., Miller J.E. Clostridium botulinum and the clinical laboratorian: a detailed review of botulism, including biological warfare ramifications of botulinum toxin. Arch. Pathol. Lab. Med. 2004, 128:653-662.
20. Chen F., Kuziemko G.M., Amersdorfer P., Wong C., Marks J.D., Stevens R.C. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect. Immun. 1997, 65:1626-1630.
21. Coffield J.C. Botulinum neurotoxin: the neuromuscular junction revisited. Crit. Rev. Neurobiol. 2003, 15:175-195.
22. Therapeutic Uses of Botulinum Toxin 2007, Springer. G. Cooper (Ed.).
23. Couesnon A., Pereira Y., Popoff M.R. Receptor-mediated transcytosis of botulinum neurotoxin A through intestinal cell monolayers. Cell. Microbiol. 2008, 10:375-387.
24. Couesnon A., Shimizu T., Popoff M.R. Differential entry of botulinum neurotoxin A into neuronal and intestinal cells. Cell. Microbiol. 2009, 11:289-308.
25. DasGupta B.R., Boroff D.A. Separation of toxin and hemagglutinin from crystalline toxin of Clostridium botulinum type A by anion exchange chromatography and determination of their dimensions by gel filtration. J. Biol. Chem. 1968, 243:1065-1072.
26. DasGupta B.R., Sugiyama H.A. A common subunit structure in Clostridium botulinum type A, B, and E toxins. Biochem. Biophys. Res. Commun. 1972, 48:108-112.
27. Dezfulian M., Bartlett J.G. Kinetics of growth and toxigenicity of Clostridium botulinum in experimental wound botulism. Infect. Immun. 1985, 49:452-454.
28. Dolman C.E., Iida H. Type E botulism: its epidemiology, prevention and specific treatment. Can. J. Public Health 1963, 54:293-308.
29. Eisele K.-H., Fink K., Vey M., Taylor H.V. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011, 57:555-565.
30. Eleopra R., Tugnoli V., Rossetto O., De Grandis D., Montecucco C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci. Lett. 1998, 256:135-138.
31. Elias Md., Al-Saleem F.H., Ancharski D.M., Singh A., Nasser Z., Olson R.M., Simpson L.L. Evidence that botulinum toxin receptors on epithelial cells and on neuronal cells are not identical: Implications for development of a non-neurotropic vaccine. J. Pharmacol. Exp. Ther. 2011, 336:973-982.
32. Fagan R.P., McLaughlin J.B., Middaugh J.P. Persistence of botulinum toxin in patients' serum: Alaska, 1959-2007. J. Infect. Dis. 2009, 199:1029-1031.
33. Fernandez-Salas E., Steward L.E., Ho H., Garay P.E., Sun S.W., Gilmore M.A., Ordas J.V., Wang J., Francis J., Aoki K.R. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc. Natl. Acad. Sci. 2004, 101:3208-3213.
34. Fischer A., Montal M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J. Biol. Chem. 2007, 282:29604-29611.
35. Fischer A., Montal M. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc. Natl. Acad. Sci. 2007, 104:10447-10452.
36. Foran P.G., Mohammed N., Lisk G.O., Nagwaney S., Lawrence G.W., Johnson E., Smith L., Aoki K.R., Dolly J.O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E and F compared with the long lasting type A. J. Biol. Chem. 2003, 278:1363-1371.
37. Fujinaga Y., Inoue K., Watanabe S., Yokota K., Hirai Y., Nagamachi E., Oguma K. The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine, leading to the efficient absorption of the toxin. Microbiology 1997, 143:3841-3847.
38. Fujinaga Y., Inoue K., Nomura T., Sasaki J., Marvaud J.C., Popoff M.R., Kozaki S., Oguma K. Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. FEBS Lett. 2000, 467:179-183.
39. Fujinaga Y., Matsumura T., Jin Y., Takegahara T., Sugawara Y. A novel function of botulinum toxin-associated proteins: HA proteins disrupt intestinal epithelial barrier to increase toxin absorption. Toxicon 2009, 54:583-586.
40. Fujinaga Y. Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin. J. Biochem. 2006, 140:155-160.
41. Gordon R.J., Lowy F.D. Bacterial infections in drug users. N. Eng. J. Med. 2005, 353:1945-1954.
42. Gu S., Rumpel S., Zhou J., Strotmeier J., Bigalke H., Perry K., Shoemaker C.B., Rummel A., Jin R. Botulinum neurotoxin is shielded by NTNH in an interlocked complex. Science 2012, 335:977-981.
43. Hansen N., Tolo V. Wound botulism complicating an open fracture. J. Bone Jt. Surg. Am. 1979, 61:312-314.
44. Hasegawa K., Watanabe T., Suzuki T., Yamano A., Oikawa T., Sato Y., Kouguchi H., Yoneyama T., Niwa K., Ikeda T., Ohyama T. A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms. J. Biol. Chem. 2007, 282:24777-24783.
45. Henkel A.W., Simpson L.L., Ridge R.M.A.P., Betz W.J. Synaptic vesicle movements monitored by fluorescence recovery after photobleaching in nerve terminals stained with FM1-43. J. Neurosci. 1996, 16:3960-3967.
46. Hoch D.H., Finkelstein A., Miryam R.M., Ehrlich B.E., DasGupta B.R., Simpson L.L. Channels formed by diphtheria, botulinum and tetanus toxin in planar bilayer membranes: relevance to translocation of toxins into cells. Proc. Natl. Acad. Sci. 1985, 82:1692-1696.
47. Isacsohn M., Cohen A., Steiner A., Rosenberg P., Rudensky B. Botulism intoxication after surgery in the gut. Isr. J. Med. Sci. 1985, 21:150-153.
48. Jin Y., Takegahara Y., Sugawara Y., Matsumura T., Fujinaga Y. Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins - differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C. Microbiology 2009, 155:35-45.
49. Kalka-Moll W.M., Aurbach U., Schaumann R., Schwarz R., Seifert H. Wound botulism in injection drug users. Emerg. Infect. Dis. 2007, 13:942-943.
50. Keller J.E., Neale E.A. The role of the synaptic protein SNAP-25 in the potency of botulinum neurotoxin type A. J. Biol. Chem. 2001, 276:13476-13482.
51. Keller J.E., Neale E.A., Oyler G., Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 1999, 456:137-142.
52. Keller J.E. Recovery from botulinum neurotoxin poisoning invivo. Neuroscience 2006, 139:629-637.
53. Kiyatkin N., Maksymowych A., Simpson L.L. Induction of an immune response by oral administration of recombinant botulinum toxin. Infect. Immun. 1997, 65:4586-4591.
54. Koriazova L.K., Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol. 2003, 10:13-18.
55. Kuo C.-L., Oyler G.A., Shoemaker C.B. Accelerated neuronal recovery from botulinum neurotoxin intoxication by targeted ubiquitination. PLoS One 2011, 6:e20352.
56. Lamanna C. Hemagglutination by botulinal toxin. Proc. Soc. Exp. Biol. Med. 1948, 69:332-336.
57. Lawrence G.W., Ovsepian S.V., Wang J., Aoki K.R., Dolly J.O. Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission. Biochem. J. 2012, 441:443-452.
58. MacDonald K.L., Rutherford G.W., Friedman S.M. Botulism and botulism-like illness in chronic drug abusers. Ann. Intern. Med. 1985, 102:616-618.
59. Maksymowych A.B., Simpson L.L. Binding and transcytosis of botulinum toxin by polarized human colon carcinoma cells. J. Biol. Chem. 1998, 273:21950-21957.
60. Maksymowych A.B., Simpson L.L. Structural features of botulinum toxin that govern binding and transcytosis across polarized human intestinal cells. J. Pharmacol. Exp. Ther. 2004, 310:1-9.
61. Maksymowych A.B., Reinhard M., Malizio C.J., Goodnough M.C., Johnson E.A., Simpson L.L. Pure botulinum toxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect. Immun. 1999, 67:4708-4712.
62. Matsumura T., Jin Y., Kabumoto Y., Takegahara Y., Oguma K., Lencer W.I., Fujinaga Y. The HA proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption. Cell. Microbiol. 2008, 10:355-364.
63. Meunier F.A., Schiavo G., Molgo J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J. Physiol. 2002, 96:105-113.
64. Minton N.P. Molecular genetics of clostridial neurotoxins. Curr. Top. Microbiol. Immunol. 1995, 195:161-194.
65. Mitchell P.A., Pons P.T. Wound botulism associated with black tar heroin and lower extremity cellulitis. J. Emerg. Med. 2001, 20:371-375.
66. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 2010, 79:591-617.
67. Montecucco C., Schiavo G., DasGupta B.R. Effect of pH on the interaction of botulinum neurotoxins A, B and E with liposomes. Biochem. J. 1989, 259:47-53.
68. Montecucco C., Rossetto O., Schiavo G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 2004, 12:442-446.
69. Montecucco C. How do tetanus and botulinum toxins bind to neuronal membranes?. Trends Biochem. Sci. 1986, 11:314-317.
70. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., Sheridan R., Blake R., Smith L.A., Marks J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. 2002, 99:11346-11350.
71. Park J.-B., Simpson L.L. Inhalation poisoning and inhalation vaccination by botulinum toxin and its heavy chain component. Infect. Immun. 2003, 71:1147-1154.
72. Popoff M.R. Ecology of neurotoxigenic strains of clostridia. Curr. Top. Microbiol. Immunol. 1995, 195:1-29.
73. Raciborska D.A., Charlton M.P. Retention of cleaved synaptosome-associated protein of 25 kDa (SNAP-25) in neuromuscular junctions: a new hypothesis to explain persistence of botulinum A poisoning. Can. J. Pharmacol. 1999, 77:679-688.
74. Raffestin S., Marvaud J.C., Cerrato R., Dupuy B., Popoff M.R. Organization and regulation of the neurotoxin genes in Clostridium botulinum and Clostridium tetani. Anaerobe 2004, 10:93-100.
75. Ravichandran E., Gong Y., Al-Saleem F.H., Ancharski D.M., Joshi S.G., Simpson L.L. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J. Pharmacol. Exp. Ther. 2006, 318:1343-1351.
76. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias Md, Singh A.K., Shamim M., Gong Y., Simpson L.L. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 2007, 75:3043-3054.
77. Rossetto O., Montecucco C. Presynaptic neurotoxins with enzymatic activities. Handb. Exp. Pharmacol. 2008, 184:129-170.
78. Rummel A., Mahrhold S., Bigalke H., Binz T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular gangliosides binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 2004, 51:631-643.
79. Sakaguchi G. Clostridium botulinum toxins. Pharmacol. Ther. 1983, 19:165-194.
80. Schiavo G., Benfenati F., Poulain B., Rossetto O., Polverino de Laureto P., DasGupta B.R., Montcucco C. Tetanus and botulinum B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
81. Schiavo G., Rossetto O., Santucci A., DasGupta B.R., Montecucco C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 1992, 267:23479-23483.
82. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:717-766.
83. Sepulveda J., Mukherjee J., Tzipori S., Simpson L.L., Shoemaker C.B. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect. Immun. 2010, 78:756-763.
84. Shapiro R.L., Hatheway C., Swerdlow D.L. Botulism in the United States: a clinical and epidemiological review. Ann. Intern. Med. 1998, 129:221-228.
85. Sheth A.N., Wiersma P., Atrubin D., Dubey V., Zink D., Skinner G., Doerr F., Juliao P., Gonzalez G., Burnett C., Drenzek C., Shuler C., Austin J., Ellis A., Maslanka S., Sobel J. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin. Infect. Dis. 2008, 47:1245-1251.
86. Shi X., Curran J.E., Liao Z., Gordon R.K. The biological activity of ubiquitinated BoNT/B light chain invitro and in human SHSY-5Y neuronal cells. J. Cell. Biochem. 2009, 108:660-667.
87. Shoemaker C.B., Oyler G.A. Persistence of botulinum neurotoxin inactivation of nerve function. Curr. Top. Microbiol. Immunol. 2013, 364:179-196.
88. Simpson L.L., DasGupta B.R. Botulinum neurotoxin type E: studies on mechanism of action and on structure-activity relationships. J. Pharmacol. Exp. Ther. 1983, 224:135-140.
89. Simpson L.L., Rapport M.M. Ganglioside inactivation of botulinum toxin. J. Neurochem. 1971, 18:1341-1343.
90. Simpson L.L., Rapport M.M. The binding of botulinum toxin to membrane lipids: sphingolipids, steroids and fatty acids. J. Neurochem. 1971, 18:1751-1759.
91. Simpson L.L., Coffield J.A., Bakry N. Chelation of zinc antagonizes the neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as well as tetanus toxin. J. Pharmacol. Exp. Ther. 1993, 267:720-727.
92. Simpson L.L., Coffield J.A., Bakry N. Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J. Pharmacol. Exp. Ther. 1993, 269:256-262.
93. Simpson L.L., Maksymowych A.B., Hao S. The role of zinc binding in the biological activity of botulinum toxin. J. Biol. Chem. 2001, 276:27034-27041.
94. Simpson L.L. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J. Pharmacol. Exp. Ther. 1980, 212:16-21.
95. Simpson L.L. The origin, structure and pharmacological activity of botulinum toxin. Pharacol. Rev. 1981, 33:155-188.
96. Simpson L.L. Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins. J. Pharmacol. Exp. Ther. 1983, 225:546-552.
97. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44:167-193.
98. Simpson L.L. Botulinum toxin. Vaccines for Biodefense and Emerging and Neglected Diseases 2009, 891-917. Elsevier. L.R. Stanberry, A.D.T. Barrett (Eds.).
99. Sobel J.N., Tucker N., Sulka A., McLaughlin J., Maslanka S. Foodborne botulism in the United States. 1990-2000. Emer. Infect. Dis. 2004, 10:1606-1611.
100. Stanker L.H., Merrill P., Scotcher M.C., Cheng L.L. Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type A and their use in analysis of milk by sandwich ELISA. J. Immunol. Methods 2008, 336:1-8.
101. Swaminathan S. Molecular structures and functional relationships in clostridial neurotoxins. FEBS J. 2011, 278:4467-4485.
102. Tsai Y.C., Maditz R., Kuo C.-L., Fishman P.S., Shoemaker C.B., Oyler G.A., Weissman A.M. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc. Natl. Acad. Sci. 2010, 107:16554-16559.
103. Werner S.B., Passaro D., McGee J., Schechter R., Vugia D.J. Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin. Infect. Dis. 2000, 31:1018-1024.
104. Yowler B.C., Kensinger R.D., Schengrund C.L. Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J. Biol. Chem. 2002, 227:32815-32819.
105. Zhao H., Nakamura K., Kohda T., Mukamoto M., Kozaki S. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms. Japan. J. Infect. Dis. 2012, 65:138-145.